Actinium Highlights ATNM 400 Progress at SNMMI Conference
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400.
The data indicated that the leading drug demonstrated superior cancer cell killing in contrast to Xtandi (enzalutamide) and greater efficacy than not only Pluvicto (177Lu-PSMA-617) but also Ac-225-PSMA-617 in both laboratory and animal models. As the Actinium’s Chairman and CEO, Sandesh Seth, stated,
“ATNM-400 is the ideal cornerstone of our emerging solid tumor pipeline.”
A research laboratory arranged with a variety of test tubes filled with liquids for biopharmaceutical research.
We have seen how Xtandi, developed by Astellas and Pfizer, secured $5.9 billion in sales in 2024, with Novartis’s Pluvicto generating $1.4 billion in the same period. Since ATNM-400 is the potential monotherapy or is complementary to the existing prostate cancer treatments, we have good reason to believe that the drug will be a turnaround point for Actinium Pharmaceuticals, Inc. (NYSE:ATNM).
Actinium Pharmaceuticals, Inc. (NYSE:ATNM), based in New York, develops antibody radiation conjugates and other targeted radiotherapies to address the failures of the current oncology therapies. With two clinical-stage product candidates, Actimab-A and Iomab-ACT, the giant aims to build a hospital-focused radiotherapeutics company.
While we acknowledge the potential of ATNM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Content Original Link:
" target="_blank">
